Developing Nanoparticle-Based Therapeutics for Targeting the Microenvironment in Obesity-Induced Endometrial Cancer.
Cuatin LDP., Zhang D., Zertuche F., Mota L., Dang C., Nayak B.
Animal Study, published in Cell Mol Bioeng (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Cell Mol Bioeng (2025)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41185634
- PMCID
- PMC12579650
- DOI
- 10.1007/s12195-025-00853-2
- Citations
- 1
Abstract (original English)
Background The global rise of obesity has contributed to an increase in the incidence of endometrial cancer, the most common gynecologic malignancy. This obesity-driven increase, alongside limited therapeutic options, presents a growing public health concern. Our previous research indicated that adipose stem cells (ASCs), shed from fat depots, infiltrate the endometrium via the circulation in endometrial cancer patients with obesity. Furthermore, ASCs elicited the malignant transformation of endometrial epithelial cells (EECs) and fostered an oncogenic microenvironment driven by the plasminogen activator inhibitor 1 (PAI-1). Objective To develop a nanoparticle-based system to deliver PAI-1 siRNA targeting the microenvironment of obesity-driven endometrial tumors. Methods We developed 2D and 3D spheroid in vitro systems modeling the effects of endometrial microenvironment on ASCs to identify ASC integrin targeting markers. We also analyzed gonadal fat and uterine tissue from obese (ob/ob) mice, validating these ASC integrin markers in vivo. For targeted delivery, we engineered lipid-coated mesoporous silica nanoparticles (LCMSNs) loaded with PAI-1 siRNA. These nanoparticles were administered to ob/ob mice via intraperitoneal injection to evaluate targeting and therapeutic efficiency. Results ASCs exposed to an oncogenic endometrial microenvironment showed increased integrin alph
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.